In a fight against the novel coronavirus, researchers have found that medication for high blood pressure could improve COVID-19 survival rates and reduce the severity of the infection.
Two blood pressure-lowering drug classes, called ACE inhibitors and ARBs, came under scrutiny after the US Centres for Disease Control and Prevention reported in April that 72% of hospitalised COVID-19 patients 65 or older had hypertension.
Researchers said cancer patients should be encouraged to raise the issue of consuming aspirin with their doctors.
The unique feature of this drug is that it has no side effects and its effectiveness depends on the estrogen receptors in the majority of breast tumors.
Taking them for long periods may cause dangerous complications of the heart and circulatory system, which may result in death.
Use of higher doses of aspirin poses various risks depending on the stage of pregnancy.
Respiratory tract infections (RTIs) can affect the sinuses, throat, airways or lungs, but most get better without treatment.
"Since it was tried on patients with different variants of COVID-19, we expect it to be effective on Omicron as on other variants," Professor Iqbal Chaudhry, director of the International Centre for Chemical and Biological Science (ICCBS) where trials were conducted, told reporters.
The initiative aims to provide affordable medicines to uninsured and low-income expat patients or those whose insurance is not covering the cost of treatment of the following diseases; pulmonary arterial hypertension, multiple myeloma, active ulcerative colitis.